摘要
目的探讨对妊娠高血压患者采用硫酸镁药物进行治疗后获得的临床效果。方法方便选取2017年1月—2021年3月收治的99例妊娠高血压患者进行药物治疗研究,随机分为硝苯地平组(采用硝苯地平药物进行治疗)和硫酸镁组(采用硫酸镁药物进行治疗),分别为49例以及50例。比较两组患者药物治疗总有效率、妊娠结局(新生儿窘迫、早产、产后出血)、血压水平(收缩压、舒张压)以及血液流变学指标水平[全血还原黏度(WBRV)、红细胞压积(HCT)、血浆黏度(PV)、红细胞聚集指数(RAI)、纤维蛋白原(FIB)]。结果硫酸镁组药物治疗总有效率(96.00%)高于硝苯地平组(77.55%),差异有统计学意义(χ^(2)=7.384,P=0.007);硫酸镁组妊娠不良结局(新生儿窘迫、早产、产后出血)总发生率(2.00%)低于硝苯地平组(30.61%),差异有统计学意义(χ^(2)=14.952,P<0.001);治疗前,硫酸镁组收缩压、舒张压同硝苯地平组比较,差异无统计学意义(P>0.05);治疗后,硫酸镁组收缩压(121.59±5.49)mmHg、舒张压(80.25±6.58)mmHg低于硝苯地平组收缩压(138.79±6.25)mmHg、舒张压(96.13±8.13)mmHg,差异有统计学意义(t=14.556、10.693,P<0.001);治疗前,硫酸镁组WBRV、HCT、PV、RAI、FIB同硝苯地平组比较,差异无统计学意义(P>0.05);治疗后,硫酸镁组WBRV(18.59±1.45)mPa·s、HCT(46.31±5.81)%、PV(2.06±0.31)mPa·s、RAI(2.69±0.33)、FIB(3.41±0.79)g/L均低于硝苯地平组WBRV(22.33±2.32)mPa·s、HCT(52.33±4.15)%、PV(3.02±0.33)mPa·s、RAI(3.17±0.33)、FIB(4.26±0.79)g/L,差异有统计学意义(t=9.639、5.922、14.922、7.236、5.353,P<0.001)。结论硫酸镁药物有效应用后,疗效获得明显增强,妊娠结局、血压水平、血液流变学指标可获得显著改善,可促进妊娠高血压患者总体预后水平的显著提升。
Objective To explore the clinical effects of magnesium sulfate in patients with pregnancy-induced hypertension.Methods Ninety-nine patients with hypertension in pregnancy who were admitted from January 2017 to March 2021 were conveniently selected for drug treatment research.They were randomly divided into the nifedipine group(treated with nifedipine drugs)and the magnesium sulfate group(treated with magnesium sulfate drugs),with 49 cases and 50 cases respectively.The total effective rate of drug treatment,pregnancy outcome(neonatal distress,premature delivery,postpartum hemorrhage),blood pressure level(systolic blood pressure,diastolic blood pressure)and hemorheological index levels[whole blood reduced viscosity(WBRV),Hematocrit(HCT),plasma viscosity(PV),red blood cell aggregation index(RAI),fibrinogen(FIB)]were compared.Results The total effective rate of drug treatment in the magnesium sulfate group(96.00%)was higher than that in the nifedipine group(77.55%),and the difference was statistically significant(χ^(2)=7.384,P=0.007).The overall incidence of adverse pregnancy outcomes(neonatal distress,premature delivery,and postpartum hemorrhage)in the magnesium sulfate group(2.00%)was lower than that in the nifedipine group(30.61%),and the difference was statistically significant(χ^(2)=14.952,P<0.001).Before treatment,the systolic blood pressure and diastolic blood pressure of the magnesium sulfate group were compared with the nifedipine group,and there was no statistically significant difference(P>0.05).After treatment,the systolic blood pressure(121.59±5.49)mmHg and diastolic blood pressure(80.25±6.58)mmHg in the magnesium sulfate group were lower than the systolic blood pressure(138.79±6.25)mmHg and diastolic blood pressure(96.13±8.13)mmHg in the nifedipine group,and the difference was statistically significant(t=14.556,10.693,P<0.001).Before treatment,the magnesium sulfate group WBRV,HCT,PV,RAI,FIB compared with the nifedipine group,there was no statistically significant difference(P>0.05).After treatment
作者
徐红香
XU Hongxiang(Department of Obstetrics and Gynecology,Xuyi County Hospital of Traditional Chinese Medicine,Xuyi,Jiangsu Province,211700 China)
出处
《中外医疗》
2021年第35期131-134,共4页
China & Foreign Medical Treatment
关键词
妊娠高血压
硫酸镁
治疗总有效率
妊娠结局
血压水平
血液流变学指标
Hypertension in pregnancy
Magnesium sulfate
Total effective rate of treatment
Pregnancy outcome
Blood pressure level
Hemorheology index
